prikaz prve stranice dokumenta What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
  Download
PDF 4.89 MB
Scientific paper - Original scientific paper
What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
Human Vaccines & Immunotherapeutics, 19 (2023), 3; 2270310. https://doi.org/10.1080/21645515.2023.2270310
Ravlić, Sanda; Kurtović, Tihana; Cvetko Krajinović, Lidija; Hećimović, Ana; Miloš, Marija; Mateljak Lukačević, Sanja; Markotić, Alemka; Halassy, Beata

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Ravlić, S., Kurtović, T., Cvetko Krajinović, L., Hećimović, A., Miloš, M., Mateljak Lukačević, S. ... Halassy, B. (2023). What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?. Human Vaccines & Immunotherapeutics, 19. (3). doi: 10.1080/21645515.2023.2270310

Ravlić, Sanda, et al. "What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?." Human Vaccines & Immunotherapeutics, vol. 19, no. 3, 2023. https://doi.org/10.1080/21645515.2023.2270310

Ravlić, Sanda, Tihana Kurtović, Lidija Cvetko Krajinović, Ana Hećimović, Marija Miloš, Sanja Mateljak Lukačević, Alemka Markotić and Beata Halassy. "What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?." Human Vaccines & Immunotherapeutics 19, no. 3 (2023). https://doi.org/10.1080/21645515.2023.2270310

Ravlić, S., et al. (2023) 'What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?', Human Vaccines & Immunotherapeutics, 19(3). doi: 10.1080/21645515.2023.2270310

Ravlić S, Kurtović T, Cvetko Krajinović L, Hećimović A, Miloš M, Mateljak Lukačević S, and sur.. What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?. Human Vaccines & Immunotherapeutics [Internet]. 2023 October 31 [cited 2024 November 29];19(3). doi: 10.1080/21645515.2023.2270310

S. Ravlić, et al., "What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?", Human Vaccines & Immunotherapeutics, vol. 19, no. 3, October 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:749533. [Accessed: 29 November 2024]

Metadata
Title (english)What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
AuthorSanda Ravlić
AuthorTihana Kurtović
AuthorLidija Cvetko Krajinović
AuthorAna Hećimović
AuthorMarija Miloš
AuthorSanja Mateljak Lukačević
AuthorAlemka Markotić
AuthorBeata Halassy
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
In the COVID-19 pandemic, we have witnessed an impressive speed in the development of effective vaccines approved for human use, based on clinical studies comparing their efficacy to placebo. A head-to-head comparison of the neutralizing antibody (NAb) responses elicited by four vaccines used in Europe during 2021 (BNT162b2, mRNA-1273, ChAdOx nCoV-19, Ad26.COV2.S) and their comparison to NAb responses in convalescents showed that while the amount was comparable, NAbs induced by natural infection were of superior quality. The highly scattered immune responses elicited by the four vaccines were equalled by booster mRNA vaccination, reaching the highest, plateau level of NAb at the population level. Equally high NAbs were induced in convalescents after a single injection of either vaccine. The use of wild-type virus as a challenge in the NAb determination revealed that NAbs produced by disease were better activators of the complement system than NAbs induced by vaccination. The contribution of spike protein-specific IgGs to the SARS-CoV-2 neutralization was lower in convalescents compared to vaccinees, indicating that those who recovered from COVID-19 were armed with antibodies of additional specificities and/or classes that contributed to virus neutralization. Such findings point to the need to re-examine the correctness of certain epidemiological measures applied in the current epidemic. We also highlight the importance of a standardized approach in assessing humoral immunity by the usage of the most comprehensive assays as early as possible in future epidemics.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleHuman Vaccines & Immunotherapeutics
Numberingvol. 19, no. 3, 2270310
p-ISSN2164-5515
e-ISSN2164-554X
DOIhttps://doi.org/10.1080/21645515.2023.2270310
URN:NBNurn:nbn:hr:184:749533
Publication2023-10-31
ProjectNumber: N/A
Title (croatian): Centar izvrsnosti za virusnu imunologiju i cjepiva
Title (english): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Acronym: CERVirVac
Leader: Stipan Jonjić
Jurisdiction: Croatia
Funding stream: ZCI
ProjectNumber: KK.011.1.01.0006
Title (croatian): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Leader: Stipan Jonjić
Jurisdiction: Croatia
Document URLhttps://www.tandfonline.com/doi/full/10.1080/21645515.2023.2270310
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-31 09:35:06